Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Paramagnetic Resonance of Cobalt(II) Trispyrazolylmethanes and Counterion Association.

Marts AR, Kaine JC, Baum RR, Clayton VL, Bennett JR, Cordonnier LJ, McCarrick R, Hasheminasab A, Crandall LA, Ziegler CJ, Tierney DL.

Inorg Chem. 2017 Jan 3;56(1):618-626. doi: 10.1021/acs.inorgchem.6b02520.

PMID:
27977149
2.

Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.

Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Matucci-Cerinic M, Furst DE; DUAL-1 Investigators.; DUAL-2 Investigators..

JAMA. 2016 May 10;315(18):1975-88. doi: 10.1001/jama.2016.5258.

PMID:
27163986
3.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group..

Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5.

PMID:
26135703
4.

Tofacitinib versus methotrexate in rheumatoid arthritis.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators..

N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476.

5.

Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.

Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC.

Arthritis Rheumatol. 2014 Aug;66(8):1987-97. doi: 10.1002/art.38687.

6.

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.

Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, Dicarlo J, Friedman J, Devenport J, Troum O.

Ann Rheum Dis. 2014 May;73(5):810-6. doi: 10.1136/annrheumdis-2013-204762.

7.

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.

Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, Wallace D, Martin R, Phillips K, Kaine JL, Dong H, Salinger D, Stevens E, Russell CB, Chung JB.

Arthritis Res Ther. 2013 Oct 25;15(5):R164. doi: 10.1186/ar4347.

8.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzov√° D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA; ORAL Scan Investigators..

Arthritis Rheum. 2013 Mar;65(3):559-70. doi: 10.1002/art.37816.

9.

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS; TEAR Investigators..

Arthritis Rheum. 2012 Sep;64(9):2824-35. doi: 10.1002/art.34498.

10.

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, Pappu R, Delaet I, Pans M, Ludivico C.

Ann Rheum Dis. 2012 Jan;71(1):38-44. doi: 10.1136/annrheumdis-2011-200344.

11.

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.

Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group..

J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292.

12.
13.

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM; IMAGE Investigators..

Ann Rheum Dis. 2011 Jan;70(1):39-46. doi: 10.1136/ard.2010.137703.

PMID:
20937671
14.

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.

Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial..

Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9.

15.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial..

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765.

16.

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W; ACTION Study Group..

Arthritis Rheum. 2008 Sep;58(9):2652-61. doi: 10.1002/art.23732.

17.

Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension trial.

White WB, Cleveland JM, Rolleri RL; Ramipril-Hydrochlorothiazide Study Group..

J Hum Hypertens. 2008 Aug;22(8):559-68. doi: 10.1038/jhh.2008.26.

PMID:
18463672
18.

Abatacept for the treatment of rheumatoid arthritis: A review.

Kaine JL.

Curr Ther Res Clin Exp. 2007 Nov;68(6):379-99. doi: 10.1016/j.curtheres.2007.12.001.

19.
20.

Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.

Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA; Tcrolimus Rheumatoid Arthritis Study Group..

Arthritis Rheum. 2003 Dec;48(12):3328-37.

Items per page

Supplemental Content

Loading ...
Support Center